Limonoid and SGLT-2 Inhibitor Combination for Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current SGLT-2 inhibitors for diabetes treatment often cause severe side effects such as hypoglycemia and urinary tract infections due to their high doses required for effective glucose lowering, necessitating a combination therapy that enhances therapeutic effects while reducing SGLT-2 inhibitor doses and side effects.
Innovation Solution
A combination product comprising a limonoid compound and a SGLT-2 inhibitor, where the limonoid compound, such as limonin or its derivatives, is administered with SGLT-2 inhibitors like canagliflozin, dapagliflozin, or empagliflozin, either simultaneously or sequentially, to enhance hypoglycemic effects and reduce the required dose of SGLT-2 inhibitors, thereby minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of SGLT-2 inhibitors are used to achieve effective glucose lowering, then the hypoglycemic effect is improved, but side effects such as hypoglycemia and urinary tract infections increase
Solution Approach 1:
The patent combines limonoid compounds with SGLT-2 inhibitors to create a synergistic therapeutic effect. The limonoid compound enhances the hypoglycemic action of the SGLT-2 inhibitor, allowing for reduced dosing of the SGLT-2 inhibitor while maintaining or improving glucose control efficacy, thereby reducing dose-dependent side effects such as urinary tract infections and hypoglycemia
Solution Approach 2:
The invention uses a composite pharmaceutical formulation containing both limonoid compounds and SGLT-2 inhibitors. This composite approach leverages the complementary mechanisms of action: limonoids improve insulin sensitivity and glucose metabolism while SGLT-2 inhibitors block renal glucose reabsorption, achieving enhanced glycemic control with lower doses of each component
2Device complexity
If SGLT-2 inhibitors are used alone, then the mechanism is simple, but the required dose is high leading to severe side effects
Solution Approach 1:
The patent merges two therapeutic agents with different mechanisms of action: limonoid compounds that improve peripheral insulin sensitivity and glucose uptake, and SGLT-2 inhibitors that block renal glucose reabsorption. This combination allows for lower dosing of the SGLT-2 inhibitor component while achieving synergistic glucose-lowering effects, thereby reducing side effects without complicating the treatment approach
Data Source
AI summary
A combination product comprising limonoids (and pharmaceutically-acceptable derivatives, esters, stereoisomers, salts or prodrugs thereof) and a sodium-glucose co-transporter-2 (SGLT-2) inhibitors (such as canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, luseogliflozin, and tofogliflozin). The present invention also relates to the use of the combination product in treating and/or preventing diseases related to diabetes.